Yesterday, I couldn’t stand being inside my skin. It felt like a prison, this body of mine that didn’t know what it wanted or why it was here. I squirmed through the day, fussing and eating and eating ...

Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression ...

My mixed episodes feel like agitated depression — restless, racing, and raw. I’ve learned to recognize the signs and hold onto structure to find stability. It’s dusk and I’m sitting with my arms ...

Credit: Getty Images. Lumateperone 42mg given once daily met the primary endpoint in the study. Lumateperone monotherapy was associated with significant improvement of major depressive episodes in ...

What Is Bysanti, and Why Does It Matter? Bysanti (milsaperidone) is a new FDA-approved oral medicine for treating certain mental health conditions in adults. It belongs to a group of medicines called ...

An antipsychotic approved by the FDA in 2009 to treat schizophrenia has now been green-lighted for use in bipolar 1 disorder. Iloperidone (Fanapt) is now FDA-approved for adults with bipolar 1 ...

When lithium or valproate aren't enough, ‘add-on’ treatments like atypical antipsychotics can help. Discover 7 options to discuss with your doctor.

Bipolar disorder is a complex psychiatric disorder, characterized by fluctuations between episodes of (hypo)mania and depression. It is estimated to affect around 40 to 50 million people worldwide.